Charles Sawyers

Charles Sawyers at Memorial Sloan Kettering is a precision oncology pioneer who co-developed enzalutamide and contributed to understanding BCR-ABL resistance mechanisms that led to second-generation CML inhibitors. His laboratory work on androgen receptor splice variants established mechanisms of enzalutamide resistance in prostate cancer. He is the recipient of the Lasker Award and has led the Cancer Genome Atlas (TCGA) and other large-scale genomic projects. He has been at the forefront of precision oncology drug development for multiple cancer types.